MET and lung cancer: In contrast to patients with MET exon 14 skipping, patients with MET copy number gain were more prone to have late stage disease, poor differentiation, and acinar/solid/invasive mucinous adenocarcinoma (Table 4), indicating that MET copy number gain is a late event in lung cancer.